FDA OKs Merck tablet to reduce ragweed allergies

by The Associated Press

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.

Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily, from three months before ragweed season begins until it ends, for a few years. The Food and Drug Administration approved it for patients aged 18 through 65.

Whitehouse Station, N.J.-based Merck's tablet for spring grass allergies, Grastek, was approved Monday for patients aged 5 to 65.

Both offer an alternative to medicines that just temporarily relieve symptoms or years of uncomfortable allergy shots.

The shots and tablets work by gradually tamping down immune response to allergy-triggering substances and reducing sneezing, runny noses and itchy, watery eyes.

Ragwitek and Grastek should be available in pharmacies by April 30.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck says FDA reviewing its ragweed allergy therapy

May 08, 2013

Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Merck: FDA reviewing tablet to eliminate allergy

Mar 27, 2013

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

Recommended for you

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments